Your session is about to expire
← Back to Search
Cohort 1 (Mild Impairment): Brensocatib for Kidney Failure
Study Summary
The primary purpose of the study is to determine the pharmacokinetics (PK) following a single oral dose administration of brensocatib, safety, and tolerability of brensocatib when administered to participants with impaired renal function and in healthy participants.
- Kidney Failure
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 3 trial • 406 Patients • NCT04817332Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Frequently Asked Questions
Are there any current openings for participants in this clinical trial?
"Clinicaltrials.gov indicates that this research is still recruiting participants, having been posted on the 20th of July 2021 and recently updated on December 21st 2022."
Is this trial available to individuals aged 80 or older?
"According to the prerequisites for this trial, all participants must be between 18 and 80 years old."
How many participants are currently being enrolled in this clinical trial?
"Affirmative. According to clinicaltrials.gov, this medical trial is recruiting patients as of now; the study was initially published on July 20th 2021 and last revised on December 21st 2022. Altogether, 30 participants are being enrolled from two separate centres."
What criteria is necessary for individuals to qualify for this clinical trial?
"To be considered for the trial, applicants must have declining kidney performance and an age between 18-80. Currently, 30 participants are being recruited to partake in this medical experiment."
What are the safety profiles of patients in Cohort 1 (Mild Impairment) taking Brensocatib?
"After careful consideration, the safety of Brensocatib for patients with mild impairment was rated an 1 due to limited clinical data surrounding its efficacy and security."
Share this study with friends
Copy Link
Messenger